Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294767 | 0.89 | MAPT (0.73) | GAAPOLBSMN1; SMN2NPC1HPGD | |
| Bucetin SCHEMBL11647704 | 0.85 | KMT2A (0.58) | GAAPOLBSMN1; SMN2NPC1HPGD | |
| Bufexamac SCHEMBL17710313 | 0.84 | SMN1; SMN2 (0.67) | GAAPOLBSMN1; SMN2NPC1HPGD | |
| SCHEMBL9312707 | 0.83 | POLB (1.00) | POLBSMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL9978996 | 0.83 | POLB (0.69) | GAAPOLBSMN1; SMN2NPC1HPGD | |
| SCHEMBL9979411 | 0.83 | POLB (0.69) | GAAPOLBSMN1; SMN2NPC1HPGD | |
| SCHEMBL12445438 | 0.82 | POLB (0.83) | POLBSMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL26488 | 0.81 | MAPT (0.65) | GAAPOLBSMN1; SMN2NPC1HPGD | |
| SCHEMBL8984662 | 0.81 | LTA4H (0.70) | POLBSMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL25086 | 0.80 | POLB (0.80) | POLBSMN1; SMN2NPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1658 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| US-11872307-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2024-01-16 | — | — | US | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2023205619-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | claimed |
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | OCULAR THERAPEUTIX INC (US) | 2023-09-14 | — | — | US | claimed |
| EP-4236943-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE AGENT | Ocular Therapeutix, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| EP-1252133-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-10-30 | — | — | EP | claimed |
| EP-1192129-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-04-03 | — | — | EP | claimed |
| EP-1169298-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1998052616-A2 | NONSTEROIDAL ANTIRHEUMATIC AGENTS OR THROMBOCYTE-AGGLUTINATION INHIBITORS TO IMPROVE REPRESENTATION OF VESSELS, LYMPH NODES AND BONE MARROW WITH PHARMACEUTICAL PREPARATIONS CONTAINING PARTICLES, VESICLES OF POLYMERS | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1998-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | ERBB2, BTK, ERBB3 | GAA 800/4885POLB 4423/4885SMN1; SMN2 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.